PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, reports that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc . investment opportunity to institutional investors.
Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (“PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.
CARBO Ceramics Inc. (NYSE: CRR) plans to release earnings results for the third quarter of 2010 on October 28, 2010, and will host a conference call at 10:00 a.m. Central Time (11:00 a.m. Eastern) that day. The call will be hosted by Gary Kolstad, President and CEO, and Ernesto Bautista, III, Vice President and CFO.
CARBO is the world’s largest supplier of ceramic proppant for fracturing oil and gas wells; the provider of the world’s most popular fracture simulation software; and a provider of fracture design and consulting services. The Company also provides a broad range of technologies for spill prevention, containment and countermeasures, along with geotechnical monitoring.
Cardinal Health (NYSE:CAH) plans to release first-quarter financial results for its fiscal 2011 on Oct. 28, prior to the opening of trading on the New York Stock Exchange.
The company has scheduled a webcast and conference call for Oct. 28 at 8:30 a.m. EDT to discuss first-quarter results. To access the call and corresponding slide presentation, go to the Investor page at cardinalhealth.com/investors or dial 617-213-4848 passcode 23771725.
Headquartered in Dublin, Ohio, Cardinal Health, Inc. is a $99 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while reducing costs, improving efficiency and quality, and increasing profitability. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation’s largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #17 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide.
CareFusion (NYSE: CFN), a leading, global medical device company, has announced it has entered into an agreement with Healthpoint, Ltd. to market and sell innovative surgical scrub solutions, including Surgicept Waterless Surgical Hand Scrub, Triseptin Water-Aided Surgical Scrub and Triseptin Hand and Body Antiseptic.
It has been established that HAIs can be reduced with proper hand antisepsis by health care professionals prior to surgery, which limits the transfer of potentially harmful microorganisms to the skin of their patients. Recommendations and guidelines, including those from the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), state that health care professionals should clean their hands with an alcohol-based antimicrobial solution prior to patient contact or putting on gloves. However, adherence to these guidelines is lower than it should be; studies have shown an average compliance rate of 40 percent. According to the CDC, poor compliance is due to multiple factors, including perceived lack of time and irritation or dryness caused by the antiseptic.
CareFusion is a global corporation serving the health care industry with products and services that help hospitals measurably improve patient care. The company develops market-leading technologies including Alaris IV pumps, Pyxis automated dispensing and patient identification systems, AirLife, AVEA and LTV series of ventilators and respiratory products, ChloraPrep skin prep products, MedMined services for infection surveillance, V. Mueller and Snowden-Pencer surgical instruments and NeuroCare diagnostic products. CareFusion employs more than 15,000 people across its global operations.
No comments:
Post a Comment